Neonatal surfactant therapy beyond respiratory distress syndrome
Copyright © 2023. Published by Elsevier Ltd..
Whilst exogenous surfactant therapy is central to the management of newborn infants with respiratory distress syndrome, its use in other neonatal lung diseases remains inconsistent and controversial. Here we discuss the evidence and experience in relation to surfactant therapy in newborns with other lung conditions in which surfactant may be deficient or dysfunctional, including meconium aspiration syndrome, pneumonia, congenital diaphragmatic hernia and pulmonary haemorrhage. We find that, for all of these diseases, administration of exogenous surfactant as bolus therapy is frequently associated with transient improvement in oxygenation, likely related to temporary mitigation of surfactant inhibition in the airspaces. However, for none of them is there a lasting clinical benefit of surfactant therapy. By virtue of interrupting disease pathogenesis, lavage therapy with dilute surfactant in MAS offers the greatest possibility of a more pronounced therapeutic effect, but this has yet to be definitively proven. Lavage therapy also involves a greater degree of procedural risk.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Seminars in fetal & neonatal medicine - 28(2023), 6 vom: 15. Dez., Seite 101501 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dargaville, Peter A [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 16.12.2023 Date Revised 04.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.siny.2023.101501 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365315788 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365315788 | ||
| 003 | DE-627 | ||
| 005 | 20240108141721.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.siny.2023.101501 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1248.xml |
| 035 | |a (DE-627)NLM365315788 | ||
| 035 | |a (NLM)38040584 | ||
| 035 | |a (PII)S1744-165X(23)00077-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dargaville, Peter A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Neonatal surfactant therapy beyond respiratory distress syndrome |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.12.2023 | ||
| 500 | |a Date Revised 04.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023. Published by Elsevier Ltd. | ||
| 520 | |a Whilst exogenous surfactant therapy is central to the management of newborn infants with respiratory distress syndrome, its use in other neonatal lung diseases remains inconsistent and controversial. Here we discuss the evidence and experience in relation to surfactant therapy in newborns with other lung conditions in which surfactant may be deficient or dysfunctional, including meconium aspiration syndrome, pneumonia, congenital diaphragmatic hernia and pulmonary haemorrhage. We find that, for all of these diseases, administration of exogenous surfactant as bolus therapy is frequently associated with transient improvement in oxygenation, likely related to temporary mitigation of surfactant inhibition in the airspaces. However, for none of them is there a lasting clinical benefit of surfactant therapy. By virtue of interrupting disease pathogenesis, lavage therapy with dilute surfactant in MAS offers the greatest possibility of a more pronounced therapeutic effect, but this has yet to be definitively proven. Lavage therapy also involves a greater degree of procedural risk | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Congenital diaphragmatic hernia | |
| 650 | 4 | |a Meconium aspiration syndrome | |
| 650 | 4 | |a Pneumonia | |
| 650 | 4 | |a Pulmonary haemorrhage | |
| 650 | 4 | |a Pulmonary surfactants | |
| 650 | 4 | |a infant newborn | |
| 650 | 7 | |a Surface-Active Agents |2 NLM | |
| 650 | 7 | |a Pulmonary Surfactants |2 NLM | |
| 650 | 7 | |a Lipoproteins |2 NLM | |
| 700 | 1 | |a Herting, Egbert |e verfasserin |4 aut | |
| 700 | 1 | |a Soll, Roger F |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Seminars in fetal & neonatal medicine |d 2004 |g 28(2023), 6 vom: 15. Dez., Seite 101501 |w (DE-627)NLM15349798X |x 1878-0946 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2023 |g number:6 |g day:15 |g month:12 |g pages:101501 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.siny.2023.101501 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2023 |e 6 |b 15 |c 12 |h 101501 | ||